Sustained release of liposome-encapsulated enrofloxacin after intramuscular administration in rabbits.
Enrofloxacin was encapsulated in multilamellar liposomes composed of phosphatidylcholine and cholesterol (molar ratio, 1:1), and its potential use as sustained release formulation was evaluated. The encapsulated drug was administered IM to rabbits (n = 6). Results indicated that absorption rate was slow, compared with previous studies; additionally, peak concentration was lower (0.5 +/- 0.1 microgram/ml), and the time to peak concentration was considerably longer for liposome-encapsulated enrofloxacin (1.5 +/- 1.08 hours) than for unencapsulated drug. Apparent elimination half-life of drug in the body was significantly (P < 0.05) increased (4.05 +/- 1.08 hours) when it was administered encapsulated in liposomes. Large-size liposomes containing enrofloxacin administered IM to rabbits gave sustained drug release from the injection site, providing therapeutic and prolonged plasma concentrations of drug in the body.
Cabanes
A
A
Department of Peptides, CID, CSIC, Barcelona, Spain.
Reig
F
F
Antón
J M
JM
Arboix
M
M
D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D000077422:Enrofloxacin; D024841:Fluoroquinolones; D006207:Half-Life; D007273:Injections, Intramuscular; D008081:Liposomes; D008297:Male; D010743:Phospholipids; D015363:Quinolones / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D011817:Rabbits; D013997:Time Factors
D000890:Anti-Infective Agents; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D024841:Fluoroquinolones; D008081:Liposomes; D010743:Phospholipids; D015363:Quinolones; D000077422:Enrofloxacin